Swedish Orphan Biovitrum Submits Application for Orfadin® Oral Suspension to FDA
Published: Oct 29, 2013
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company's application for Orfadin oral suspension has been submitted to the US Food and Drug Administration (FDA). This new dosage form has been developed to facilitate the ease and accuracy of administration for Orfadin in paediatric patients as well as to increase convenience for patients and their caregivers.
Help employers find you! Check out all the jobs and post your resume.